Intensity Therapeutics In... (INTS)
Intensity Therapeutics Statistics
Share Statistics
Intensity Therapeutics has 15.18M shares outstanding. The number of shares has increased by 10.71% in one year.
| Shares Outstanding | 15.18M |
| Shares Change (YoY) | 10.71% |
| Shares Change (QoQ) | 0.5% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.26M |
| Failed to Deliver (FTD) Shares | 859 |
| FTD / Avg. Volume | 2.48% |
Short Selling Information
The latest short interest is 44.28K, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 44.28K |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -1.5 and the forward PE ratio is -1.95. Intensity Therapeutics's PEG ratio is 0.1.
| PE Ratio | -1.5 |
| Forward PE | -1.95 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 8.39 |
| P/FCF Ratio | -1.61 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intensity Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.92 |
| Quick Ratio | 1.92 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.25M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -56.14% in the last 52 weeks. The beta is 4.59, so Intensity Therapeutics's price volatility has been higher than the market average.
| Beta | 4.59 |
| 52-Week Price Change | -56.14% |
| 50-Day Moving Average | 2.2 |
| 200-Day Moving Average | 3.28 |
| Relative Strength Index (RSI) | 43.38 |
| Average Volume (20 Days) | 34.61K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -16.59M |
| Net Income | -16.27M |
| EBITDA | -16.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.17 |
Balance Sheet
The company has 2.59M in cash and 138K in debt, giving a net cash position of 2.45M.
| Cash & Cash Equivalents | 2.59M |
| Total Debt | 138K |
| Net Cash | 2.45M |
| Retained Earnings | -66.78M |
| Total Assets | 4.78M |
| Working Capital | 1.61M |
Cash Flow
In the last 12 months, operating cash flow was -15.22M and capital expenditures 0, giving a free cash flow of -15.22M.
| Operating Cash Flow | -15.22M |
| Capital Expenditures | 0 |
| Free Cash Flow | -15.22M |
| FCF Per Share | -1.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for INTS is $8.5, which is 325% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 325% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -20.36 |
| Piotroski F-Score | 1 |